Drug manufacturer Gilead accuses some Florida STD clinics in a lawsuit of misusing their 340B eligibility to defraud the company of at least $43 million on purchases of and reimbursement for PrEP medicines. | Source: Shutterstock
Gilead Accuses Florida 340B STD Clinics of “at Least $43 Million” in Fraudulent PrEP Transactions
Drug manufacturer Gilead Sciences has accused two groups of Florida health care providers, pharmacies, and labs—including five sexually transmitted disease clinics with multiple locations that participate in the 340B program and two contract pharmacies—of “captur[ing] tens of millions of dollars in profits through fraudulent enrollments and reimbursement claims” on Gilead’s HIV pre-exposure prophylaxis drugs Truvada and Descovy.
“Defendants have made at least $43 million in profits from their schemes since February 2018,” Gilead alleges in a Nov. 3 lawsuit.